• About us
• Contact

Advertisement

Collaboration › Details

BioNTech–JPMorgan Chase: investor conference, 202301 supply service BioNTech presents at JP Morgan Healthcare Conference 2023

 

	Period	2023-01-10
	Region	San Francisco, CA
	Country	United States (USA)
	Partner, 1st	BioNTech SE (Nasdaq: BNTX)
	Group	BioNTech (Group)
	Partner, 2nd	J.P. Morgan Securities LLC
	Product	J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco
	Product 2	mRNA technology
	Person	Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
	Person 2	Maas, Sylke (BioNTech 202005 VP Investor Relations + Business Strategy)

BioNTech SE. (12/28/22). "Press Release: BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference". Mainz.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.

A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.com/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.


About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit www.BioNTech.com.


CONTACT

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

Record changed: 2023-01-05

Advertisement

More documents for BioNTech (Group)

• [1] BioNTech SE. (8/17/23). "Press Release: BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer". Tübingen & Boston, MA....
• [2] CureVac N.V.. (8/17/23). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update". Tübingen & Boston, MA....
• [3] Biotheus Inc.. (7/19/23). "Press Release: Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech". Zhuhai....
• [4] Zhejiang Doer Biologics Co., Ltd.. (7/10/23). "Press Release: Doer Biologics Announces License Agreement with BioNTech". Hangzhou....
• [5] BioNTech SE. (6/29/23). "Press Release: BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC". Mainz & Rockville, MD....
• [6] BioNTech AG. (3/20/23). "Press Release: BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications". Mainz & Rockville, MD....
• [7] BioNTech AG. (3/14/23). "Press Release: Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years". New York & Mainz....
• [8] BioNTech AG. (3/13/23). "Press Release: Update on First BioNTainer for African-based mRNA Manufacturing Facility". Mainz & Kigali....
• [9] BioNTech AG. (3/1/23). "Press Release: BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel". Jerusalem....
• [10] BioNTech SE. (2/10/23). "Press Release: Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program". New York, NY & Mainz....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.